Prospective evaluation of the efficacy, safety, and optimal biomarker enrichment strategy for nangibotide, a TREM-1 inhibitor, in patients with septic shock (ASTONISH): a double-blind, randomised, controlled, phase 2b trial
ASTONISH investigators, Bruno François, Simon Lambden, Tom Fivez, Sebastien Gibot, Marc Derive, Jean Marie Grouin, Margarita Salcedo-Magguilli, Jérémie Lemarié, Nicolas De Schryver, Ville Jalkanen, Tarik Hicheur, Jean Jacques Garaud, Valérie Cuvier, Ricard Ferrer, Morten Bestle, Ville Pettilä, Jean Paul Mira, Camille Bouisse, Emmanuelle MercierJoris Vermassen, Vincent Huberlant, Isabelle Vinatier, Nadia Anguel, Mitchell Levy, Pierre François Laterre
Research output: Contribution to journal › Article › Scientific › peer-review
22Citations
(Scopus)
Fingerprint
Dive into the research topics of 'Prospective evaluation of the efficacy, safety, and optimal biomarker enrichment strategy for nangibotide, a TREM-1 inhibitor, in patients with septic shock (ASTONISH): a double-blind, randomised, controlled, phase 2b trial'. Together they form a unique fingerprint.